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Since their introduction, the SSRI class of drugs has become the most widely used 
of all the antidepressants. The major advantage of the SSRIs over other classes of 
antidepressant treatments, is their selectivity for the inhibition of reuptake, thus 
facilitating their therapeutic effect by enhancing the availability of 5-HT at the 
synapse. However there are still some side effects associated with SSRI 
antidepressant treatment as mentioned in chapter 2. Also, SSRIs have a 
considerable time delay (2-6 weeks) before the onset of beneficial effect is 
observed (Blier & De Montigny, 1994). Amazingly, despite the variety of animal 
models of depression, there are few models currently capable of detecting a faster 
onset of action of one antidepressant over another. It is clear that with the need to 
find fasting acting antidepressants, we need complimentary animal models to 
screen these compounds. Some current animal models of depression generate 
positive results with antidepressants after 24 hours or less after their 
administration (Horovitz et al, 1965; Porsolt et al, 1978; Lucki, 1997), while 
chronic treatment is required before an anti-depressant effect is observed in other 
models (Jesberger & Richardson, 1985; Willner & Sanger, 1997; Katz et al, 1997; 
Kelly et al, 1997). It has been questioned whether animal models which detect 
antidepressant-like activity in 24 hours or less, actually reflect the mechanisms 
relevant to those underlying clinical efficacy. One model which requires chronic 
antidepressant treatment before a change is detected is the attenuation of 
hyperactivity in the olfactory bulbectomized model. It has been shown that many 
neurochemical, endocrine and immunological changes which occur in the brain 
with this animal model correspond to changes seen in clinical depression (Kelly et 
al, 1997). Interestingly, this model has been put forward as a possible model for 
detecting a faster onset of antidepressant effects, however it is believed further 
refinement of the model may be required (Cryan et al, 1998). The chronic mild 
stress model has also been suggested as an animal model for early onset of 
depression (Willner & Sanger, 1997). The pharmacological validation of the 
model is extensive as compared to other animal models of depression, and 
prolonged antidepressant treatment is required before a reversal in the stress 
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deficits is observed. Also, using this model, there have been no reported false 
negatives or false positives (Willner & Sanger, 1997). 
The mechanism behind this delay of onset has received much attention 
since the introduction of the SSRIs. The general belief is that the delay is because 
of a desensitization of receptors due to prolonged 5-HT exposure. Following the 
initial increase in serotonin with SSRI administration, autoreceptors on the 
serotonergic neuron reduce the firing rate of the neuron as well as the release of 5-
HT at the terminal. There have been many investigations into the manipulation of 
this delay with compounds which prevent this autoreceptor activity (see below).  
With current antidepressant treatment, and the delay in onset of effects, 
not only is the patient suffering after treatment, but many are at an increased risk 
of suicide, as many adverse side effects are worst during the initial phases of 
treatment. As mentioned in earlier chapter, there are a number of symptoms which 
overlap between depression and anxiety, and a number of studies have 
investigated the co-administration of anxiolytic agents with SSRIs (see below). 
 Another interesting observation is that there is still a significant amount of 
depressed individuals who do not respond to antidepressant treatment. Many 
investigators are trying to determine the reason behind this phenomenon amongst 
the non-responders and ways to normalise levels of neurotransmitters in the 
patient. Taken together, it is clear that further work is needed to understand the 
aetiology of depression, but the enhancement of effects of current antidepressant 
treatments may help in this understanding. 
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SSRI Combination Studies with 5-HT receptors 
compounds 
 
SSRIs and 5-HT1A receptor antagonism 
 
As mentioned above, following SSRI administration there is a certain negative 
feedback on the serotonergic neuron which reduces firing. Microdialysis and 
electrophysiological studies have shown that prolonged treatment with SSRIs 
leads to  a functional desensitization of somatodenedritic 5-HT1A receptors 
leading to disinhibition in the regulation of extracellular 5-HT (Blier & 
DeMontigny, 1994; Hjorth & Auerbach, 1996; Hjorth & Bengtsson, 2000; Artigas 
et al, 1996). The combination of 5-HT1A antagonists with SSRIs has been shown 
to prevent the 5-HT1A-mediated decrease in firing which allows further release of 
5-HT in terminal areas (Barnes & Sharp, 1999; Gartside et al, 1999; Gobert & 
Millan, 1999; Hjorth & Bengtsson, 2000; Millan et al, 2000; Romero et al, 1996).  
 In a number of behavioural models of depression, the antidepressant 
activity of SSRIs was enhanced with the co-administration of 5-HT1A antagonists 
(Mitchell & Redfern, 1997; Millan et al, 1998, 2000; Knobelman et al, 2001; 
Blier & Ward, 2003, Celada et al, 2004; Cryan et al, 2005). This suggests a 
beneficial role in the combination strategy. 
It is believed that by preventing the negative feedback of the 5-HT1A 
autoreceptor on serotonergic neurons, we can mimic the effect of chronic SSRI 
treatment (i.e. 5-HT1A auroreceptor desensitization), and reduce the time before 
onset of therapeutic effects is observed. In clinical trials, where the 5-HT1A 
antagonists, pindolol was co-administered with SSRIs a slight reduction in time of 
onset was observed in a subset of patients (McAskill et al, 1998; Artigas et al, 
1994, 2001; Perez et al, 2001; Blier et al, 2003; Segrave & Nathan, 2005). 
However evaluation of this augmentation strategy has yielded controversial 
results depending on the setup of the clinical trial (Artigas et al, 1994; Blier & 
Bergeron, 1995; Blier et al, 1997; Dinan & Scott, 1996; Perez et al, 1999). As 
well as co-administration of 5-HT1A compounds with SSRIs a number of 
companies have been working on developing a single ligand with dual affinity. 
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Indeed, a number of compounds have been synthesized coupling known 5-HT1A 
antagonists (pindolol, propranolol and penbutolol) with SSRIs and milnacipran 
(Perez et al, 1998). These compounds displayed similar or better potency at the 5-
HT1A receptor, but only had a moderate affinity for the 5-HT uptake site. 
 
SSRIs and 5-HT1B/1D receptor antagonism 
 
Similarly, to the 5-HT1A receptor, the 5-HT1B/1D receptors have also been shown to 
act as autoreceptors on the serotonergic neuron (Barnes & Sharp, 1999; Hjorth et 
al, 2000; Millan et al, 2000; Blier, 2003). Also, long term administration of SSRIs 
is accompanied by a decrease in the density of terminal 5-HT1B autoreceptors 
(Blier et al, 1988; Neumaier et al, 1996; Anthony et al, 2000). These receptors 
have also been investigated as possible targets for antagonism in order to 
potentiate the anti-depressant effect of SSRIs with regard to enhanced effect and 
speed of onset. Unfortunately there is a lack of selective antagonists for either the 
5-HT1B or 5-HT1D receptor, and this had hindered further elucidation of the role of 
the respective receptors. Blockade of 5-HT1B receptors in combination with SSRIs 
have shown an augmentation in the extracellular 5-HT in a number of studies 
(Davidson & Stamford, 1995; Millan et al, 1999, 2000; Hervas et al, 2000; Hjorth 
et al, 2000; Malagie et al, 2001). This finding has been reinforced by the fact that 
genetically modified 5-HT1B knockout mice had a higher basal 5-HT output 
(Trillat et al, 1997; Knobelman et al, 2001; De Groote et al, 2002) and a greater 
response to SSRI treatment than their wild-type counterparts (Mayorga et al, 
2001).  
  
Though evidence exists for a possible beneficial effect of the combination of 5-
HT1B/1D antagonists with SSRIs, no clinical studies have yet been performed. It is 
important to realise that with the administration of these 5-HT1B antagonists there 
will be antagonism not only on the presynaptic 5-HT receptors, but also on 
receptors located postsynaptically on other neurotransmitter systems, which may 
exacerbate further side effects.  
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SSRIs and 5-HT1A receptor agonism 
 
There is experimental and clinical data to support a role for postsynaptic 5-HT1A 
receptors in the control of mood (Lucki et al, 1994; De Vry, 1995; Millan et al, 
2000; Blier, 2003; Celada et al, 2004), and a number of behavioural animal 
studies have reported antidepressant effects with the administration of 5-HT1A 
agonists (Deakin, 1993; Pecknold, 1994; Lucki et al, 1994; Schreiber et al, 1994; 
De Vry, 1995; Overstreet et al, 2003). The 5-HT1A agonist, buspirone, displays 
antidepressant activity in rodents (Lucki, 1991; Lucki et al, 1994; De Vry, 1995), 
and humans (Robinson et al, 1990; Pecknold, 1994; De Vry, 1995; Masuda et al, 
2002; Blier, 2003). However, neither buspirone, nor any other 5-HT1A agonist has 
reached the market as monotherapy due to side effects including dizziness, nausea 
and insomnia (Robinson et al, 1990; Wilcox et al, 1996; Lapierre et al, 1998; 
Blier, 2003). Interestingly, some studies have reported that it accelerates and 
enhances the antidepressant action of SSRIs (Bouwer & Stein, 1997; Marangell, 
2000; Appelberg et al, 2001). The facilitatory influence of buspirone upon the 
antidepressant effect cannot be exclusively attributed to 5-HT1A receptor 
activation, as it has dopaminergicD2 antagonistic properties and also gets 
metabolized to a compound which acts as an antagonist of alpha-2 adrenergic 
receptors, and it is believed that the faster onset of action may be due to its 
anxiolytic properties (De Vry, 1995; Millan, 2003). Due to the augmenting effect 
of buspirone on time of onset, an experimental analysis of its mode of action may 
reveal future targets for antidepressant combination studies. 
 
SSRIs and 5-HT2 receptor antagonism 
 
Clinical evidence for a role of 5-HT2 receptors in depression comes from 
alterations in platelets and post-mortem tissue of depressed patients (Cryan & 
Leonard, 2000). In clinical studies, the combination of SSRIs with 5-HT2 
antagonists is believed to be beneficial over SSRI therapy alone in a number of 
ways. A number of newer antidepressants possess affinity for the 5-HT2A receptor 
(mirtazapine, mianserin, trazodone and nefazodone – see chapter 2) and are 
believed to have a better side effects profile (Carpenter et al, 1999; Greene & 
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Barbhaiya, 1997). Also, some of the side effects of SSRIs are believed to be 
attributed to 5-HT2 receptors including sleep disturbance and sexual dysfunction 
(Thase, 1999). Interestingly, it has been shown that SSRIs increase, whereas 
tricyclic antidepressants decrease, binding of ligands to the 5-HT2A receptor 
(Massou et al, 1997; Attar-Levy et al, 1999). Likewise, many antidepressants 
down-regulate 5-HT2A receptors after repeated treatment (Gray & Roth, 2001). 
Experiments involving the manipulation of pyramidal neurons in prefrontal cortex 
have illustrated a role for the 5-HT2A receptor in the mechanism of action of 
SSRIs via a long feedback loop (Celada et al, 2004; Adell et al, 2005).  
More recently, the 5-HT2C receptor has been shown to augment the 
increase in extracellular 5-HT with SSRIs in microdialysis, and in 5-HT2C 
knockout mice, there was an augmented antidepressant effect with the 
administration of SSRIs as compared to their wild-type counterparts (Cremers et 
al, 2004). It has also been shown in animal models, that the 5-HT2C receptor plays 
a role in the mediation of anxiety (Tecott & Barondes, 1996; Cervo & Samanin, 
1995; Kennett et al, 1995, 1996; Griebel et al, 1997; Millan et al, 2001; Millan, 
2003). As 5-HT2 receptors are not considered to be autoreceptors, they have only 
recently been considered to mediate a role in the mechanism of action of 
antidepressants, albeit via other neurotransmitter systems. 
 
SSRIs and other 5-HT receptor compounds 
 
It is believed that 5-HT5 may also be located as autoreceptors on serotonergic 
pathways (Oliver et al, 2000; Kinsey et al, 2001; Millan, 2003; Nelson, 2004; 
Serrats et al, 2004). However their functional significance as compared to 5-HT1A 
and 5-HT1B receptors remains unclear (Millan, 2003), and to date, no 5-HT5 
antagonists or 5-HT5/5-HT reuptake inhibitors have been reported.  
 5-HT7 receptors have also been reported to attenuate the activity of raphe 
serotonergic neurons (Hjorth et al, 2000; Celada et al, 2004), although this effect 
is mediated indirectly via a long feedback loop involving GABAergic neurons. 
Similarly to the 5-HT5 receptor, the effect of the 5-HT7 receptors is relatively 
minor compared to the role of the 5-HT1A receptor. To date, no 5-HT7 compounds 
or dual 5-HT7/ 5-HT reuptake inhibitors have been developed.  
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 Recently, 5-HT4 receptors have received interest due to a facilitatory role 
on the raphe (Lucas et al, 2005), their favourable influence upon cognitive 
performance, and their prokinetic properties in the gut which may alleviate 
gastrointestinal discomfort related to SSRI treatment. 
 5-HT3 receptors antagonists have recently been shown to reduce the 
effects of nausea, which is a common complaint with SSRI treatment, particularly 
at the start of treatment.  
 
SSRI Combination Studies with adrenergic receptors 
 
It has known that similar to 5-HT1A autoreceptors, there is a desensitization of 
noradrenergic alpha-2 autoreceptors (Blier & De Montigny, 1994; Kreiss & 
Lucki, 1995; Haddjeri et al, 1998; Invernizzi & Garatinni, 2004) with long term 
antidepressant treatment. Alpha-2 receptor antagonists have also been shown to 
provide a facilitatory role in the release of monoamines (Artigas, 1993; Gobert et 
al, 1997; Hjorth et al, 2000; Millan et al, 2000; Invernizzi & Garatinni, 2004).  
Indeed, the activation of presynaptic alpha-2 receptors located on serotonergic 
neurons (Mongeau & Blier, 1993; Feuerstein et al, 1993) has been shown to 
decrease the firing of the serotonergic neuron and hence the release of serotonin 
(Starke & Montel, 1973; Frankhuyzena & Mulder, 1980). Animal studies 
involving alpha-2 knockout mice were shown to modify the response of mice to 
aversive stimuli and their behaviour in models of stress and depression (Sallinen 
et al, 1999; Millan et al, 2000; Weikop et al, 2004). The administration of alpha-2 
compounds with SSRIs and SNRIs were shown to further increase monoamine 
release in terminal areas (Gobert et al, 1997; Millan et al, 2000). Considering the 
inhibitory effect of the alpha-2 adrenoceptor on serotonergic function, it has been 
hypothesized that the combination of an alpha-2 adrenoceptor antagonist with an 
SSRI may result in enhanced postsynaptic serotonergic transmission. Consistent 
with this hypothesis, it was determined that yohimbine, an alpha-2 adrenoceptor 
antagonist, accelerated the onset of action of fluoxetine and possible potentiated 
its efficacy (Sanacora et al, 2004). However, yohimbine has also been reported to 
have agonist properties at 5-HT1A receptors (Winter & Rabin, 1993; Newman-
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Tancredi & Chaput, 1998; Millan et al, 2000), so an agonistic role at these 
receptors cannot be discounted.  
 Recently, a number of alpha-2 adrenoceptor antagonist/5-HT reuptake 
inhibitors have been described (Andres et al, 2003, 2005; Pastor et al, 2004; Cordi 
et al, 2001), and reported to have similar responses on monoamine levels as 
reported by alpha-2 antagonist with concomitant SSRI administration (Gobert et 
al, 1997; Millan et al, 2000). Furthermore, in behavioural models of 
antidepressant activity, they exert their actions more potently and more rapidly 
that of SSRIs, NARIs and SNRIs. These mixed alpha-2 adrenoceptor antagonist/ 
5-HT reuptake inhibitors possess procognitive properties and are devoid of the 
sexual dysfunction as seen with SSRI treatment. However, there are concerns 
regarding the potential anxiogenic and cardiovascular effects, particularly at the 
start of treatment (Millan, 2000).  
 There is substantial evidence that alpha-1 adrenergic compounds influence 
5-HT release, the firing of serotonergic neurons and/or the mechanism of action of 
SSRIs and SNRIs (Rouquier et al, 1994; Koch et al, 2004; Baraban & 
Aghajanian, 1980; Routledge et al, 1994; Hjorth et al, 1995; Pudovkina et al, 
2003; Zhang et al, 2000; Adell & Artigas, 1999; Hopwood & Stamford, 2001). 
Indeed, Weikop et al (2004) reported that part of the increase in 5-HT due to 
venlafaxine may be due to alpha-1 receptors. However, due to cardiovascular 
effects, clinical studies involving alpha-1 compounds with SSRIs have not yet 
been performed.  
 There are a number of studies comparing the antidepressant efficacy of 
selective NRIs or TCAs with noradrenaline reuptake inhibition properties to SSRI 
antidepressant treatments (Anderson & Tomenson, 1995; Montgomery et al, 
1994; de Jonghe et al, 1991; Roth et al, 1990; Bowden et al, 1993; Roose et al, 
1994; Brunello et al, 2002). However, very few studies have been performed 
involving the co-administration of selective noradrenaline reuptake inhibitors with 
serotonin reuptake inhibitors in the clinic (Camarasa et al, 2005; Devarajan and 
Dursun, 2000; Dursun & Devarajan, 2001). Reboxetine is a highly selective 
norepinephrine reuptake inhibitor (Frazer, 2001) currently the only one available 
on the market, and as shown in many of these studies is just as effective and well-
tolerated as many of the SSRI treatments.  
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In recent years there has been a keen interest in dual action 
antidepressants, and combination strategies where known antidepressants are co-
administered with selective receptor agonists or antagonists (Linner et al, 2004; 
Weikop et al, 2004; Millan et al, 2003). Venlafaxine (Thase et al, 2001; Thase et 
al, 2003; Dierick et al, 1996; Poirier & Boyer, 1999), duloxetine (Detke et al, 
2004; Goldstein et al, 2002), milnacipran (Morishita & Arita, 2004; Lopez-Ibor et 
al, 2004; Bisserbe, 2002; Clerc et al, 2001), mirtazepine (Szegedi et al, 2003; 
Wade et al, 2003) are some examples which show clinical efficacy and often 
exhibit a shorter onset of action.  
 
SSRI Combination Studies with GABAergic receptors 
 
Gamma-aminobutyric acid (GABA) is the principal predominant inhibitory 
neurotransmitter in the brain, and exerts its effects via ionotropic (chloride-
permeable) GABAA receptors, and metabotropic (Gi/o-coupled) GABAB receptors 
(Bowery et al, 2002; Millan, 2003; Mohler et al, 2002; Bettler et al, 2004). Both 
GABAA (Gao et al, 1993; Rodriguez-Pallares et al, 2001) and GABAB receptors 
(Serrats et al, 2003, 2005; Abellan et al, 2000; Varga et al, 2002; Wirtshafter & 
Sheppard, 2001) have been localized on raphe serotonergic neurons, and it has 
been proposed that modulation of these receptors may impact on serotonergic 
neurons, or terminal 5-HT release. The GABAA receptor has binding sites for a 
number of ligands including benzodiazepines, barbiturates, ethanol, and steroid 
hormones. In certain cases some depressed patients are co-treated with 
benzodiazepines to treat the co-morbidity of anxiety with depression. Previous 
preclinical studies have shown that benzodiazepines decrease the basal 
extracellular concentration of serotonin in various brain regions in rats and 
guinea-pigs (Rex et al, 1993; Pei et al, 1989). The major use of benzodiazepines 
with concomitant SSRI treatment is in the treatment of anxiety and panic 
disorders, however, physical dependency can develop with long term use of 
benzodiazepines. It is generally believed that GABAA receptors do not have a 
direct involvement upon the core systems of clinical depression, and evidence for 
the involvement of GABAA receptors in animal models of depression is 
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unconvincing (Nagatani et al, 1987; Semba et al, 1989; Nakagawa et al, 1996; 
Brambilla et al, 2003). 
 Far more convincing data exists for the involvement of GABAB receptors 
in the aetiology of depression. Compared to GABAA receptors, the influence of 
GABAB receptors upon neuronal excitability is more transient and more 
prolonged. GABAB receptors exist at both pre- and post-synaptic locations, and 
while activation of the post-synaptic GABAB receptor opens K
+
-channels, 
activation of pre-synaptic receptors leads to a reduction in Ca
2+
 influx (Thompson 
& Gahwiler, 1992; Bowery et al, 2002; Bettler et al, 2004; Enna & Bowery, 
2004). GABAB receptors exist as heterodimers consisting of complimentary 
GABAB1 and GABAB2 subunits, each encoded for by two separate genes 
(Kaupmann et al, 1997; Jones et al, 1998; Bettler et al, 2004). The GABAB1 
subunit bears the binding site for GABA and competitive ligands, and exists as 
two separate isoforms (GABAB1A and GABAB1B) which may determine the 
whether the receptors are located pre- or post-synaptically (Kaupmann et al, 1997; 
Calver et al, 2002; Millan et al, 2003; Bettler et al, 2004), though this has not yet 
been fully confirmed.  
The GABAB2 does not recognise GABA, but possesses an allosteric 
binding site, which allows for further modification of the GABA-GABA receptor 
complex (Bettler et al, 2004; Binet et al, 2004; Cryan & Kaupmann et al, 2005; 
Urwyler et al, 2005; Pin et al, 2004). One proposed mechanism is that the binding 
of GABA, or GABA agonists, to the GABAB1 subunit causes a conformational 
change in the receptor complex which opens the allosteric site for manipulation 
(Pin et al, 2004). 
Animal studies involving GABAB knockout mice has provided some 
insight to the role of GABAB receptors in depression, as knockout mice displayed 
an ‘antidepressant-like’ phenotype in behavioural paradigms (Mombereau et al, 
2004, 2005). Also in behavioural studies where the GABAB agonist, baclofen, 
was administered, it was observed that there was a ‘pro-depressive’ profile, or that 
baclofen prevented the actions of other antidepressants (Lloyd & Pichat, 1987, 
Lloyd et al, 1989; Nakagawa et al, 1996a, b, c; Brambilla et al, 2003). 
Conversely, selective GABAB antagonists display an antidepressant-like profile 
(Nakagawa et al, 1996a, b, c; Mombereau et al, 2004a, b; Slattery et al, 2005) 
similarly to those seen with SSRI administration. 
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Despite the results of animal experiments, one drawback is the possibility 
of pronounced anxiogenic effects at the onset of antidepressant treatment, as 
GABAB knockout mice were shown to display an anxious profile. To summarize, 
the co-administration of GABAB agonists or antagonists may be plausible if they 
could target pre- or post-synaptic GABAB receptors. Also, the effects may be 
further modified by allosteric modulation of the GABAB2 subunit. However, 
further work needs to be performed to determine if either the pre- or post-synaptic 
GABAB receptors can be selectively activated, and whether this would prove 
beneficial in the treatment of depression. 
 
Other SSRI Combination Studies  
 
The SSRI combination studies have provided an improved insight into new 
theories behind the biochemistry and mechanism of action of SSRIs. Many new 
drugs are in preclinical and clinical trials based on results seen in SSRI 
combination studies. Perhaps new combination strategies or novel drugs will offer 
a faster onset, better efficacy, and better toleration in the treatment of depression. 
Although many other combination studies have been performed with SSRIs, many 
of these are beyond the scope of this thesis. Such combination studies include 
SSRIs in combination with the dopamine reuptake inhibitor, bupropion (Bodkin et 
al, 1997; Kennedy et al, 2002), Dopamine D2/D3 receptor antagonists (Millan et al, 
2004; Szegedi et al,1997; Goldberg et al, 1999), histamine receptor antagonists 
(Hancock & Fox, 2004; Vohora, 2004), antipsychotics (Zhang et al, 2000; 
Shelton, 2003; Koch et al, 2004; Brunello et al, 1995; Meltzer et al, 2003; Hertel 
et al, 1999; Mauri et al, 2004), neuropeptides (Kramer et al, 1998; Rupniak & 
Kramer, 1999; Blier et al, 2004; Montgomery et al, 2004; Lieb et al, 2002) as 
well as many more classes of receptor subtypes and neuromodulator systems. 





Abellan M. T., Jolas T., Aghajanian G. K. and Artigas F. (2000) Dual control of dorsal raphe 
serotonergic neurons by GABA(B) receptors. Electrophysiological and microdialysis studies. 
Synapse 36, 21-34. 
Adell A. and Artigas F. (1999) Regulation of the release of 5-hydroxytryptamine in the median 
raphe nucleus of the rat by catecholaminergic afferents. Eur J Neurosci 11, 2305-2311. 
Anderson I. M. and Tomenson B. M. (1995) Treatment discontinuation with selective serotonin 
reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. Bmj 310, 1433-1438. 
Andres J. I., Alcazar J., Alonso J. M., Alvarez R. M., Cid J. M., De Lucas A. I., Fernandez J., 
Martinez S., Nieto C., Pastor J., Bakker M. H., Biesmans I., Heylen L. I. and Megens A. A. (2003) 
Synthesis of 3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, displaying combined 5-HT uptake 
inhibiting and alpha(2)-adrenoceptor antagonistic activities: a novel series of potential 
antidepressants. Bioorg Med Chem Lett 13, 2719-2725. 
Andres J. I., Alcazar J., Alonso J. M., Alvarez R. M., Bakker M. H., Biesmans I., Cid J. M., De 
Lucas A. I., Fernandez J., Font L. M., Hens K. A., Iturrino L., Lenaerts I., Martinez S., Megens A. 
A., Pastor J., Vermote P. C. and Steckler T. (2005) Discovery of a new series of centrally active 
tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor 
blocking activity. J Med Chem 48, 2054-2071. 
Anthony J. P., Sexton T. J. and Neumaier J. F. (2000) Antidepressant-induced regulation of 5-
HT(1b) mRNA in rat dorsal raphe nucleus reverses rapidly after drug discontinuation. J Neurosci 
Res 61, 82-87. 
Appelberg B. G., Syvalahti E. K., Koskinen T. E., Mehtonen O. P., Muhonen T. T. and 
Naukkarinen H. H. (2001) Patients with severe depression may benefit from buspirone 
augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, 
randomized, double-blind, placebo wash-in study. J Clin Psychiatry 62, 448-452. 
Artigas F. (1993) 5-HT and antidepressants: new views from microdialysis studies. Trends 
Pharmacol Sci 14, 262. 
Artigas F., Perez V. and Alvarez E. (1994) Pindolol induces a rapid improvement of depressed 
patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 51, 248-251. 
Artigas F., Romero L., de Montigny C. and Blier P. (1996) Acceleration of the effect of selected 
antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 19, 378-383. 
Artigas F., Celada P., Laruelle M. and Adell A. (2001) How does pindolol improve antidepressant 
action? Trends Pharmacol Sci 22, 224-228. 
Attar-Levy D., Martinot J. L., Blin J., Dao-Castellana M. H., Crouzel C., Mazoyer B., Poirier M. 
F., Bourdel M. C., Aymard N., Syrota A. and Feline A. (1999) The cortical serotonin2 receptors 
studied with positron-emission tomography and [18F]-setoperone during depressive illness and 
antidepressant treatment with clomipramine. Biol Psychiatry 45, 180-186. 
Baraban J. M. and Aghajanian G. K. (1980) Suppression of serotonergic neuronal firing by alpha-
adrenoceptor antagonists: evidence against GABA mediation. Eur J Pharmacol 66, 287-294. 
Barnes N. M. and Sharp T. (1999) A review of central 5-HT receptors and their function. 
Neuropharmacology 38, 1083-1152. 
Bettler B., Kaupmann K., Mosbacher J. and Gassmann M. (2004) Molecular structure and 
physiological functions of GABA(B) receptors. Physiol Rev 84, 835-867. 
Chapter 3 
92 
Binet V., Goudet C., Brajon C., Le Corre L., Acher F., Pin J. P. and Prezeau L. (2004) Molecular 
mechanisms of GABA(B) receptor activation: new insights from the mechanism of action of 
CGP7930, a positive allosteric modulator. Biochem Soc Trans 32, 871-872. 
Bisserbe J. C. (2002) Clinical utility of milnacipran in comparison with other antidepressants. Int 
Clin Psychopharmacol 17 Suppl 1, S43-50. 
Blier P. and de Montigny C. (1994) Current advances and trends in the treatment of depression. 
Trends Pharmacol Sci 15, 220-226. 
Blier P. and Bergeron R. (1995) Effectiveness of pindolol with selected antidepressant drugs in the 
treatment of major depression. J Clin Psychopharmacol 15, 217-222. 
Blier P. and de Montigny C. (1998) Possible serotonergic mechanisms underlying the 
antidepressant and anti-obsessive-compulsive disorder responses. Biol Psychiatry 44, 313-323. 
Blier P. and Ward N. M. (2003) Is there a role for 5-HT1A agonists in the treatment of depression? 
Biol Psychiatry 53, 193-203. 
Blier P., Bergeron R. and de Montigny C. (1997) Selective activation of postsynaptic 5-HT1A 
receptors induces rapid antidepressant response. Neuropsychopharmacology 16, 333-338. 
Blier P., Gobbi G., Haddjeri N., Santarelli L., Mathew G. and Hen R. (2004) Impact of substance 
P receptor antagonism on the serotonin and norepinephrine systems: relevance to the 
antidepressant/anxiolytic response. J Psychiatry Neurosci 29, 208-218. 
Bodkin J. A., Lasser R. A., Wines J. D., Jr., Gardner D. M. and Baldessarini R. J. (1997) 
Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant 
monotherapy. J Clin Psychiatry 58, 137-145. 
Bouwer C. and Stein D. J. (1997) Buspirone is an effective augmenting agent of serotonin 
selective re-uptake inhibitors in severe treatment-refractory depression. S Afr Med J 87, 534-537, 
540. 
Bowden C. L., Schatzberg A. F., Rosenbaum A., Contreras S. A., Samson J. A., Dessain E. and 
Sayler M. (1993) Fluoxetine and desipramine in major depressive disorder. J Clin 
Psychopharmacol 13, 305-311. 
Bowery N. G., Bettler B., Froestl W., Gallagher J. P., Marshall F., Raiteri M., Bonner T. I. and 
Enna S. J. (2002) International Union of Pharmacology. XXXIII. Mammalian gamma-
aminobutyric acid(B) receptors: structure and function. Pharmacol Rev 54, 247-264. 
Brambilla P., Perez J., Barale F., Schettini G. and Soares J. C. (2003) GABAergic dysfunction in 
mood disorders. Mol Psychiatry 8, 721-737, 715. 
Brunello N., Masotto C., Steardo L., Markstein R. and Racagni G. (1995) New insights into the 
biology of schizophrenia through the mechanism of action of clozapine. 
Neuropsychopharmacology 13, 177-213. 
Brunello N., Mendlewicz J., Kasper S., Leonard B., Montgomery S., Nelson J., Paykel E., Versiani 
M. and Racagni G. (2002) The role of noradrenaline and selective noradrenaline reuptake 
inhibition in depression. Eur Neuropsychopharmacol 12, 461-475. 
Calver A. R., Davies C. H. and Pangalos M. (2002) GABA(B) receptors: from monogamy to 
promiscuity. Neurosignals 11, 299-314. 
Camarasa X., Lopez-Martinez E., Duboc A., Khazaal Y. and Zullino D. F. (2005) 
Escitalopram/reboxetine combination in depressed patients with substance use disorder. Prog 
Neuropsychopharmacol Biol Psychiatry 29, 165-168. 
Augmentation strategies to improve the effect of SSRIs in the treatment of depression 
 
93 
Carpenter L. L., Leon Z., Yasmin S. and Price L. H. (1999) Clinical experience with mirtazapine 
in the treatment of panic disorder. Ann Clin Psychiatry 11, 81-86. 
Celada P., Puig M., Amargos-Bosch M., Adell A. and Artigas F. (2004) The therapeutic role of 5-
HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 29, 252-265. 
Cervo L. and Samanin R. (1995) 5-HT1A receptor full and partial agonists and 5-HT2C (but not 5-
HT3) receptor antagonists increase rates of punished responding in rats. Pharmacol Biochem 
Behav 52, 671-676. 
Clerc G. (2001) Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and 
noradrenaline reuptake inhibitor: a comparison with fluvoxamine. Int Clin Psychopharmacol 16, 
145-151. 
Cordi A. A., Berque-Bestel I., Persigand T., Lacoste J. M., Newman-Tancredi A., Audinot V. and 
Millan M. J. (2001) Potential antidepressants displayed combined alpha(2)-adrenoceptor 
antagonist and monoamine uptake inhibitor properties. J Med Chem 44, 787-805. 
Cremers T. I., Giorgetti M., Bosker F. J., Hogg S., Arnt J., Mork A., Honig G., Bogeso K. P., 
Westerink B. H., den Boer H., Wikstrom H. V. and Tecott L. H. (2004) Inactivation of 5-HT(2C) 
receptors potentiates consequences of serotonin reuptake blockade. Neuropsychopharmacology 29, 
1782-1789. 
Cryan J. F. and Leonard B. E. (2000) 5-HT1A and beyond: the role of serotonin and its receptors 
in depression and the antidepressant response. Hum Psychopharmacol 15, 113-135. 
Cryan J. F. and Kaupmann K. (2005) Don't worry 'B' happy! a role for GABA(B) receptors in 
anxiety and depression. Trends Pharmacol Sci 26, 36-43. 
Cryan J. F., Valentino R. J. and Lucki I. (2005) Assessing substrates underlying the behavioral 
effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 29, 
547-569. 
Davidson C. and Stamford J. A. (1995) Evidence that 5-hydroxytryptamine release in rat dorsal 
raphe nucleus is controlled by 5-HT1A, 5-HT1B and 5-HT1D autoreceptors. Br J Pharmacol 114, 
1107-1109. 
de Groote L., Olivier B. and Westenberg H. G. (2002) Extracellular serotonin in the prefrontal 
cortex is limited through terminal 5-HT(1B) autoreceptors: a microdialysis study in knockout 
mice. Psychopharmacology (Berl) 162, 419-424. 
de Jonghe F., Ravelli D. P. and Tuynman-Qua H. (1991) A randomized, double-blind study of 
fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry 24, 62-67. 
De Vry J. (1995) 5-HT1A receptor agonists: recent developments and controversial issues. 
Psychopharmacology (Berl) 121, 1-26. 
Deakin J. F., Graeff F. G. and Guimaraes F. S. (1993) Clinical implication of microdialysis 
findings. Trends Pharmacol Sci 14, 263. 
Detke M. J., Wiltse C. G., Mallinckrodt C. H., McNamara R. K., Demitrack M. A. and Bitter I. 
(2004) Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- 
and paroxetine-controlled trial. Eur Neuropsychopharmacol 14, 457-470. 
Devarajan S. and Dursun S. M. (2000) Citalopram plus reboxetine in treatment-resistant 
depression. Can J Psychiatry 45, 489-490. 
Chapter 3 
94 
Dierick M., Ravizza L., Realini R. and Martin A. (1996) A double-blind comparison of 
venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog 
Neuropsychopharmacol Biol Psychiatry 20, 57-71. 
Dinan T. G. and Scott L. V. (1996) The influence of cortisol on spontaneous and 5HT stimulated 
prolactin release in man. J Basic Clin Physiol Pharmacol 7, 45-56. 
Dursun S. M. and Devarajan S. (2001) Reboxetine plus citalopram for refractory depression not 
responding to venlafaxine: possible mechanisms. Psychopharmacology (Berl) 153, 497-498. 
Enna S. J. and Bowery N. G. (2004) GABA(B) receptor alterations as indicators of physiological 
and pharmacological function. Biochem Pharmacol 68, 1541-1548. 
Feuerstein T. J., Mutschler A., Lupp A., Van Velthoven V., Schlicker E. and Gothert M. (1993) 
Endogenous noradrenaline activates alpha 2-adrenoceptors on serotonergic nerve endings in 
human and rat neocortex. J Neurochem 61, 474-480. 
Frankhuyzen A. L. and Mulder A. H. (1980) Noradrenaline inhibits depolarization-induced 3H-
serotonin release from slices of rat hippocampus. Eur J Pharmacol 63, 179-182. 
Frazer A. (2001) Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects 
from in vitro potencies. J Clin Psychiatry 62 Suppl 12, 16-23. 
Gao B., Fritschy J. M., Benke D. and Mohler H. (1993) Neuron-specific expression of GABAA-
receptor subtypes: differential association of the alpha 1- and alpha 3-subunits with serotonergic 
and GABAergic neurons. Neuroscience 54, 881-892. 
Gartside S. E., Clifford E. M., Cowen P. J. and Sharp T. (1999) Effects of (-)-tertatolol, (-)-
penbutolol and (+/-)-pindolol in combination with paroxetine on presynaptic 5-HT function: an in 
vivo microdialysis and electrophysiological study. Br J Pharmacol 127, 145-152. 
Gobert A. and Millan M. J. (1999) Modulation of dialysate levels of dopamine, noradrenaline, and 
serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in 
association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and 5-
HT1B receptors. Neuropsychopharmacology 21, 268-284. 
Gobert A., Rivet J. M., Cistarelli L., Melon C. and Millan M. J. (1997) Alpha2-adrenergic receptor 
blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, 
dopamine, and serotonin levels in the frontal cortex of freely moving rats. J Neurochem 69, 2616-
2619. 
Goldberg J. F., Frye M. A. and Dunn R. T. (1999) Pramipexole in refractory bipolar depression. 
Am J Psychiatry 156, 798. 
Goldstein D. J., Mallinckrodt C., Lu Y. and Demitrack M. A. (2002) Duloxetine in the treatment 
of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 63, 225-231. 
Gray J. A., Sheffler D. J., Bhatnagar A., Woods J. A., Hufeisen S. J., Benovic J. L. and Roth B. L. 
(2001) Cell-type specific effects of endocytosis inhibitors on 5-hydroxytryptamine(2A) receptor 
desensitization and resensitization reveal an arrestin-, GRK2-, and GRK5-independent mode of 
regulation in human embryonic kidney 293 cells. Mol Pharmacol 60, 1020-1030. 
Greene D. S. and Barbhaiya R. H. (1997) Clinical pharmacokinetics of nefazodone. Clin 
Pharmacokinet 33, 260-275. 
Griebel G., Perrault G. and Sanger D. J. (1997) A comparative study of the effects of selective and 
non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety. 
Neuropharmacology 36, 793-802. 
Augmentation strategies to improve the effect of SSRIs in the treatment of depression 
 
95 
Haddjeri N., Blier P. and de Montigny C. (1998) Long-term antidepressant treatments result in a 
tonic activation of forebrain 5-HT1A receptors. J Neurosci 18, 10150-10156. 
Hancock A. A., Bush E. N., Jacobson P. B., Faghih R. and Esbenshade T. A. (2004) Histamine 
H(3) antagonists in models of obesity. Inflamm Res 53 Suppl 1, S47-48. 
Hertel P., Nomikos G. G. and Svensson T. H. (1999) The antipsychotic drug risperidone interacts 
with auto- and hetero-receptors regulating serotonin output in the rat frontal cortex. 
Neuropharmacology 38, 1175-1184. 
Hervas I., Queiroz C. M., Adell A. and Artigas F. (2000) Role of uptake inhibition and 
autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus 
of the rat. Br J Pharmacol 130, 160-166. 
Hjorth S. and Auerbach S. B. (1996) 5-HT1A autoreceptors and the mode of action of selective 
serotonin reuptake inhibitors (SSRI). Behav Brain Res 73, 281-283. 
Hjorth S., Bengtsson H. J., Milano S., Lundberg J. F. and Sharp T. (1995) Studies on the role of 5-
HT1A autoreceptors and alpha 1-adrenoceptors in the inhibition of 5-HT release--I. BMY7378 and 
prazosin. Neuropharmacology 34, 615-620. 
Hjorth S., Bengtsson H. J., Kullberg A., Carlzon D., Peilot H. and Auerbach S. B. (2000) 
Serotonin autoreceptor function and antidepressant drug action. J Psychopharmacol 14, 177-185. 
Invernizzi R. W. and Garattini S. (2004) Role of presynaptic alpha2-adrenoceptors in 
antidepressant action: recent findings from microdialysis studies. Prog Neuropsychopharmacol 
Biol Psychiatry 28, 819-827. 
Jones K. A., Borowsky B., Tamm J. A., Craig D. A., Durkin M. M., Dai M., Yao W. J., Johnson 
M., Gunwaldsen C., Huang L. Y., Tang C., Shen Q., Salon J. A., Morse K., Laz T., Smith K. E., 
Nagarathnam D., Noble S. A., Branchek T. A. and Gerald C. (1998) GABA(B) receptors function 
as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature 396, 674-679. 
Kaupmann K., Huggel K., Heid J., Flor P. J., Bischoff S., Mickel S. J., McMaster G., Angst C., 
Bittiger H., Froestl W. and Bettler B. (1997) Expression cloning of GABA(B) receptors uncovers 
similarity to metabotropic glutamate receptors. Nature 386, 239-246. 
Kennedy S. H., McCann S. M., Masellis M., McIntyre R. S., Raskin J., McKay G. and Baker G. B. 
(2002) Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report 
on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 63, 181-186. 
Kennett G. A., Bailey F., Piper D. C. and Blackburn T. P. (1995) Effect of SB 200646A, a 5-
HT2C/5-HT2B receptor antagonist, in two conflict models of anxiety. Psychopharmacology (Berl) 
118, 178-182. 
Kennett G. A., Wood M. D., Bright F., Cilia J., Piper D. C., Gager T., Thomas D., Baxter G. S., 
Forbes I. T., Ham P. and Blackburn T. P. (1996) In vitro and in vivo profile of SB 206553, a 
potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties. Br J Pharmacol 117, 
427-434. 
Kinsey A. M., Wainwright A., Heavens R., Sirinathsinghji D. J. and Oliver K. R. (2001) 
Distribution of 5-ht(5A), 5-ht(5B), 5-ht(6) and 5-HT(7) receptor mRNAs in the rat brain. Brain 
Res Mol Brain Res 88, 194-198. 
Knobelman D. A., Hen R., Blendy J. A. and Lucki I. (2001) Regional patterns of compensation 
following genetic deletion of either 5-hydroxytryptamine(1A) or 5-hydroxytryptamine(1B) 
receptor in the mouse. J Pharmacol Exp Ther 298, 1092-1100. 
Chapter 3 
96 
Koch S., Perry K. W. and Bymaster F. P. (2004) Brain region and dose effects of an 
olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. 
Neuropharmacology 46, 232-242. 
Kramer M. S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J. J., Reines S. A., Liu 
G., Snavely D., Wyatt-Knowles E., Hale J. J., Mills S. G., MacCoss M., Swain C. J., Harrison T., 
Hill R. G., Hefti F., Scolnick E. M., Cascieri M. A., Chicchi G. G., Sadowski S., Williams A. R., 
Hewson L., Smith D., Carlson E. J., Hargreaves R. J. and Rupniak N. M. (1998) Distinct 
mechanism for antidepressant activity by blockade of central substance P receptors. Science 281, 
1640-1645. 
Kreiss D. S. and Lucki I. (1995) Effects of acute and repeated administration of antidepressant 
drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J Pharmacol Exp Ther 
274, 866-876. 
Lapierre Y. D., Silverstone P., Reesal R. T., Saxena B., Turner P., Bakish D., Plamondon J., 
Vincent P. M., Remick R. A., Kroft C., Payeur R., Rosales D., Lam R. and Bologa M. (1998) A 
Canadian multicenter study of three fixed doses of controlled-release ipsapirone in outpatients 
with moderate to severe major depression. J Clin Psychopharmacol 18, 268-273. 
Lieb K., Treffurth Y., Berger M. and Fiebich B. L. (2002) Substance P and affective disorders: 
new treatment opportunities by neurokinin 1 receptor antagonists? Neuropsychobiology 45 Suppl 
1, 2-6. 
Linner L., Wiker C., Arborelius L., Schalling M. and Svensson T. H. (2004) Selective 
noradrenaline reuptake inhibition enhances serotonergic neuronal activity and transmitter release 
in the rat forebrain. J Neural Transm 111, 127-139. 
Lloyd K. G. and Pichat P. (1987) GABA synapses, depression, and antidepressant drugs. 
Psychopharmacol Ser 3, 113-126. 
Lloyd K. G., Zivkovic B., Scatton B., Morselli P. L. and Bartholini G. (1989) The gabaergic 
hypothesis of depression. Prog Neuropsychopharmacol Biol Psychiatry 13, 341-351. 
Lopez-Ibor J. J. and Conesa A. (2004) A comparative study of milnacipran and imipramine in the 
treatment of major depressive disorder. Curr Med Res Opin 20, 855-860. 
Lucas G., Compan V., Charnay Y., Neve R. L., Nestler E. J., Bockaert J., Barrot M. and Debonnel 
G. (2005) Frontocortical 5-HT4 receptors exert positive feedback on serotonergic activity: viral 
transfections, subacute and chronic treatments with 5-HT4 agonists. Biol Psychiatry 57, 918-925. 
Lucki I. (1991) Behavioral studies of serotonin receptor agonists as antidepressant drugs. J Clin 
Psychiatry 52 Suppl, 24-31. 
Lucki I., Singh A. and Kreiss D. S. (1994) Antidepressant-like behavioral effects of serotonin 
receptor agonists. Neurosci Biobehav Rev 18, 85-95. 
Malagie I., Trillat A. C., Bourin M., Jacquot C., Hen R. and Gardier A. M. (2001) 5-HT1B 
Autoreceptors limit the effects of selective serotonin re-uptake inhibitors in mouse hippocampus 
and frontal cortex. J Neurochem 76, 865-871. 
Marangell L. B. (2000) Augmentation of standard depression therapy. Clin Ther 22 Suppl A, A25-
38; discussion A39-41. 
Massou J. M., Trichard C., Attar-Levy D., Feline A., Corruble E., Beaufils B. and Martinot J. L. 
(1997) Frontal 5-HT2A receptors studied in depressive patients during chronic treatment by 
selective serotonin reuptake inhibitors. Psychopharmacology (Berl) 133, 99-101. 
Masuda Y., Akagawa Y. and Hishikawa Y. (2002) Effect of serotonin 1A agonist tandospirone on 
depression symptoms in senile patients with dementia. Hum Psychopharmacol 17, 191-193. 
Augmentation strategies to improve the effect of SSRIs in the treatment of depression 
 
97 
Mauri M., Volonteri L. S., Fiorentini A., Invernizzi G., Nerini T., Baldi M. and Bareggi S. R. 
(2004) Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant 
schizophrenic patients. Schizophr Res 66, 197-198. 
Mayorga A. J., Dalvi A., Page M. E., Zimov-Levinson S., Hen R. and Lucki I. (2001) 
Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) 
receptor mutant mice. J Pharmacol Exp Ther 298, 1101-1107. 
McAskill R., Mir S. and Taylor D. (1998) Pindolol augmentation of antidepressant therapy. Br J 
Psychiatry 173, 203-208. 
Meltzer H. Y. and Sumiyoshi T. (2003) Atypical antipsychotic drugs improve cognition in 
schizophrenia. Biol Psychiatry 53, 265-267; author reply 267-268. 
Millan M. J. and Brocco M. (2003) The Vogel conflict test: procedural aspects, gamma-
aminobutyric acid, glutamate and monoamines. Eur J Pharmacol 463, 67-96. 
Millan M. J., Lejeune F. and Gobert A. (2000) Reciprocal autoreceptor and heteroreceptor control 
of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to 
the actions of antidepressant agents. J Psychopharmacol 14, 114-138. 
Millan M. J., Veiga S., Girardon S. and Brocco M. (2003) Blockade of serotonin 5-HT1B and 5-
HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, 
citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to 
other 5-HT receptor subtypes. Psychopharmacology (Berl) 168, 397-409. 
Millan M. J., Gobert A., Audinot V., Dekeyne A. and Newman-Tancredi A. (1999) Inverse 
agonists and serotonergic transmission: from recombinant, human serotonin (5-HT)1B receptors to 
G-protein coupling and function in corticolimbic structures in vivo. Neuropsychopharmacology 
21, 61S-67S. 
Millan M. J., Schreiber R., Dekeyne A., Rivet J. M., Bervoets K., Mavridis M., Sebban C., 
Maurel-Remy S., Newman-Tancredi A., Spedding M., Muller O., Lavielle G. and Brocco M. 
(1998) S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-
fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A 
agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol 
Exp Ther 286, 1356-1373. 
Mitchell P. J. and Redfern P. H. (1997) Potentiation of the time-dependent, antidepressant-induced 
changes in the agonistic behaviour of resident rats by the 5-HT1A receptor antagonist, WAY-
100635. Behav Pharmacol 8, 585-606. 
Mohler H., Fritschy J. M. and Rudolph U. (2002) A new benzodiazepine pharmacology. J 
Pharmacol Exp Ther 300, 2-8. 
Mombereau C., Kaupmann K., van der Putten H. and Cryan J. F. (2004a) Altered response to 
benzodiazepine anxiolytics in mice lacking GABA B(1) receptors. Eur J Pharmacol 497, 119-120. 
Mombereau C., Kaupmann K., Froestl W., Sansig G., van der Putten H. and Cryan J. F. (2004b) 
Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of 
anxiety- and antidepressant-like behavior. Neuropsychopharmacology 29, 1050-1062. 
Mombereau C., Kaupmann K., Gassmann M., Bettler B., van der Putten H. and Cryan J. F. (2005) 
Altered anxiety and depression-related behaviour in mice lacking GABAB(2) receptor subunits. 
Neuroreport 16, 307-310. 
Mongeau R., Blier P. and de Montigny C. (1993) In vivo electrophysiological evidence for tonic 
activation by endogenous noradrenaline of alpha 2-adrenoceptors on 5-hydroxytryptamine 
terminals in the rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 347, 266-272. 
Chapter 3 
98 
Montgomery S. A., Kennedy S. H., Burrows G. D., Lejoyeux M. and Hindmarch I. (2004) 
Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation 
symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. 
Int Clin Psychopharmacol 19, 271-280. 
Montgomery S. A., Henry J., McDonald G., Dinan T., Lader M., Hindmarch I., Clare A. and Nutt 
D. (1994) Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin 
Psychopharmacol 9, 47-53. 
Morishita S. and Arita S. (2004) Differential effects of milnacipran, fluvoxamine and paroxetine 
for inhibited and agitated depression. Eur Psychiatry 19, 450-451. 
Nagatani T., Yamamoto T., Sugihara T. and Ueki S. (1987) The effect of agonists at the GABA-
benzodiazepine receptor complex on the duration of immobility of mice in the forced swimming 
test. Eur J Pharmacol 142, 17-22. 
Nakagawa Y., Ishima T., Ishibashi Y., Tsuji M. and Takashima T. (1996a) Involvement of 
GABAB receptor systems in action of antidepressants. II: Baclofen attenuates the effect of 
desipramine whereas muscimol has no effect in learned helplessness paradigm in rats. Brain Res 
728, 225-230. 
Nakagawa Y., Ishima T., Ishibashi Y., Tsuji M. and Takashima T. (1996b) Involvement of 
GABAB receptor systems in experimental depression: baclofen but not bicuculline exacerbates 
helplessness in rats. Brain Res 741, 240-245. 
Nakagawa Y., Ishima T., Ishibashi Y., Yoshii T. and Takashima T. (1996c) Involvement of 
GABA(B) receptor systems in action of antidepressants: baclofen but not bicuculline attenuates 
the effects of antidepressants on the forced swim test in rats. Brain Res 709, 215-220. 
Nelson D. L. (2004) 5-HT5 receptors. Curr Drug Targets CNS Neurol Disord 3, 53-58. 
Neumaier J. F., Szot P., Peskind E. R., Dorsa D. M. and Hamblin M. W. (1996) Serotonergic 
lesioning differentially affects presynaptic and postsynaptic 5-HT1B receptor mRNA levels in rat 
brain. Brain Res 722, 50-58. 
Newman-Tancredi A., Chaput C., Touzard M., Verriele L. and Millan M. J. (1998) Parallel 
evaluation of 5-HT1A receptor localization and functionality: autoradiographic studies with [35S]-
GTP gamma S and the novel, selective radioligand, [3H]-S 15535. Ann N Y Acad Sci 861, 263-
264. 
Oliver K. R., Kinsey A. M., Wainwright A. and Sirinathsinghji D. J. (2000) Localization of 5-
ht(5A) receptor-like immunoreactivity in the rat brain. Brain Res 867, 131-142. 
Overstreet D. H., Commissaris R. C., De La Garza R., 2nd, File S. E., Knapp D. J. and Seiden L. 
S. (2003) Involvement of 5-HT1A receptors in animal tests of anxiety and depression: evidence 
from genetic models. Stress 6, 101-110. 
Pastor J., Alcazar J., Alvarez R. M., Andres J. I., Cid J. M., De Lucas A. I., Diaz A., Fernandez J., 
Font L. M., Iturrino L., Lafuente C., Martinez S., Bakker M. H., Biesmans I., Heylen L. I. and 
Megens A. A. (2004) Synthesis of 3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, displaying 
combined 5-HT uptake inhibiting and alpha2-adrenoceptor antagonistic activities. Part 2: Further 
exploration on the cinnamyl moiety. Bioorg Med Chem Lett 14, 2917-2922. 
Pecknold J., Luthe L., Munjack D. and Alexander P. (1994) A double-blind, placebo-controlled, 
multicenter study with alprazolam and extended-release alprazolam in the treatment of panic 
disorder. J Clin Psychopharmacol 14, 314-321. 
Pei Q., Zetterstrom T. and Fillenz M. (1989) Both systemic and local administration of 
benzodiazepine agonists inhibit the in vivo release of 5-HT from ventral hippocampus. 
Neuropharmacology 28, 1061-1066. 
Augmentation strategies to improve the effect of SSRIs in the treatment of depression 
 
99 
Perez M., Pauwels P. J., Pallard-Sigogneau I., Fourrier C., Chopin P., Palmier C., Colovray V. and 
Halazy S. (1998) Design and synthesis of new potent, silent 5-HT1A antagonists by covalent 
coupling of aminopropanol derivatives with selective serotonin reuptake inhibitors. Bioorg Med 
Chem Lett 8, 3423-3428. 
Perez V., Soler J., Puigdemont D., Alvarez E. and Artigas F. (1999) A double-blind, randomized, 
placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin 
reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Arch Gen Psychiatry 56, 375-379. 
Perez V., Puiigdemont D., Gilaberte I., Alvarez E. and Artigas F. (2001) Augmentation of 
fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and 
methodologic factors. J Clin Psychopharmacol 21, 36-45. 
Pin J. P., Kniazeff J., Binet V., Liu J., Maurel D., Galvez T., Duthey B., Havlickova M., Blahos J., 
Prezeau L. and Rondard P. (2004) Activation mechanism of the heterodimeric GABA(B) receptor. 
Biochem Pharmacol 68, 1565-1572. 
Poirier M. F. and Boyer P. (1999) Venlafaxine and paroxetine in treatment-resistant depression. 
Double-blind, randomised comparison. Br J Psychiatry 175, 12-16. 
Pudovkina O. L., Cremers T. I. and Westerink B. H. (2003) Regulation of the release of serotonin 
in the dorsal raphe nucleus by alpha1 and alpha2 adrenoceptors. Synapse 50, 77-82. 
Rex A., Marsden C. A. and Fink H. (1993) Effect of diazepam on cortical 5-HT release and 
behaviour in the guinea-pig on exposure to the elevated plus maze. Psychopharmacology (Berl) 
110, 490-496. 
Robinson D. S., Rickels K., Feighner J., Fabre L. F., Jr., Gammans R. E., Shrotriya R. C., Alms D. 
R., Andary J. J. and Messina M. E. (1990) Clinical effects of the 5-HT1A partial agonists in 
depression: a composite analysis of buspirone in the treatment of depression. J Clin 
Psychopharmacol 10, 67S-76S. 
Rodriguez-Pallares J., Caruncho H. J., Lopez-Real A., Wojcik S., Guerra M. J. and Labandeira-
Garcia J. L. (2001) Rat brain cholinergic, dopaminergic, noradrenergic and serotonergic neurons 
express GABAA receptors derived from the alpha3 subunit. Receptors Channels 7, 471-478. 
Romero L., Bel N., Artigas F., de Montigny C. and Blier P. (1996) Effect of pindolol on the 
function of pre- and postsynaptic 5-HT1A receptors: in vivo microdialysis and 
electrophysiological studies in the rat brain. Neuropsychopharmacology 15, 349-360. 
Roose S. P., Glassman A. H., Attia E. and Woodring S. (1994) Comparative efficacy of selective 
serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 151, 
1735-1739. 
Roth D., Mattes J., Sheehan K. H. and Sheehan D. V. (1990) A double-blind comparison of 
fluvoxamine, desipramine and placebo in outpatients with depression. Prog 
Neuropsychopharmacol Biol Psychiatry 14, 929-939. 
Rouquier L., Claustre Y. and Benavides J. (1994) Alpha 1-adrenoceptor antagonists differentially 
control serotonin release in the hippocampus and striatum: a microdialysis study. Eur J Pharmacol 
261, 59-64. 
Routledge C., Hartley J., Gurling J., Ashworth-Preece M., Brown G. and Dourish C. T. (1994) In 
vivo characterization of the putative 5-HT1A receptor antagonist SDZ 216,525 using two models 
of somatodendritic 5-HT1A receptor function. Neuropharmacology 33, 359-366. 
Rupniak N. M. and Kramer M. S. (1999) Discovery of the antidepressant and anti-emetic efficacy 
of substance P receptor (NK1) antagonists. Trends Pharmacol Sci 20, 485-490. 
Chapter 3 
100 
Sallinen J., Haapalinna A., MacDonald E., Viitamaa T., Lahdesmaki J., Rybnikova E., Pelto-
Huikko M., Kobilka B. K. and Scheinin M. (1999) Genetic alteration of the alpha2-adrenoceptor 
subtype c in mice affects the development of behavioral despair and stress-induced increases in 
plasma corticosterone levels. Mol Psychiatry 4, 443-452. 
Sanacora G., Berman R. M., Cappiello A., Oren D. A., Kugaya A., Liu N., Gueorguieva R., Fasula 
D. and Charney D. S. (2004) Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on 
rate of antidepressant response. Neuropsychopharmacology 29, 1166-1171. 
Schreiber R., Brocco M., Gobert A., Veiga S. and Millan M. J. (1994) The potent activity of the 5-
HT1A receptor agonists, S 14506 and S 14671, in the rat forced swim test is blocked by novel 5-
HT1A receptor antagonists. Eur J Pharmacol 271, 537-541. 
Segrave R. and Nathan P. J. (2005) Pindolol augmentation of selective serotonin reuptake 
inhibitors: accounting for the variability of results of placebo-controlled double-blind studies in 
patients with major depression. Hum Psychopharmacol 20, 163-174. 
Semba J., Kuroda Y. and Takahashi R. (1989) Potential antidepressant properties of subchronic 
GABA transaminase inhibitors in the forced swimming test in mice. Neuropsychobiology 21, 152-
156. 
Serrats J., Mengod G. and Cortes R. (2005) Expression of serotonin 5-HT2C receptors in 
GABAergic cells of the anterior raphe nuclei. J Chem Neuroanat 29, 83-91. 
Serrats J., Artigas F., Mengod G. and Cortes R. (2003) GABAB receptor mRNA in the raphe 
nuclei: co-expression with serotonin transporter and glutamic acid decarboxylase. J Neurochem 
84, 743-752. 
Serrats J., Raurich A., Vilaro M. T., Mengod G. and Cortes R. (2004) 5-ht5B receptor mRNA in 
the raphe nuclei: coexpression with serotonin transporter. Synapse 51, 102-111. 
Shelton R. C. (2003) The use of antidepressants in novel combination therapies. J Clin Psychiatry 
64 Suppl 2, 14-18. 
Slattery D. A., Desrayaud S. and Cryan J. F. (2005) GABAB receptor antagonist-mediated 
antidepressant-like behavior is serotonin-dependent. J Pharmacol Exp Ther 312, 290-296. 
Starke K. and Montel H. (1973) Alpha-receptors regulate transmitter release from central 
monoamine neurones. Naturwissenschaften 60, 354. 
Szegedi A., Wetzel H., Angersbach D., Philipp M. and Benkert O. (1997) Response to treatment in 
minor and major depression: results of a double-blind comparative study with paroxetine and 
maprotiline. J Affect Disord 45, 167-178. 
Szegedi A., Muller M. J., Anghelescu I., Klawe C., Kohnen R. and Benkert O. (2003) Early 
improvement under mirtazapine and paroxetine predicts later stable response and remission with 
high sensitivity in patients with major depression. J Clin Psychiatry 64, 413-420. 
Tecott L. H. and Barondes S. H. (1996) Genes and aggressiveness. Behavioral genetics. Curr Biol 
6, 238-240. 
Thase M. E. (1999) When are psychotherapy and pharmacotherapy combinations the treatment of 
choice for major depressive disorder? Psychiatr Q 70, 333-346. 
Thase M. E. (2003) New approaches to managing difficult-to-treat depressions. J Clin Psychiatry 
64 Suppl 1, 3-4. 
Thase M. E., Entsuah A. R. and Rudolph R. L. (2001) Remission rates during treatment with 
venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178, 234-241. 
Augmentation strategies to improve the effect of SSRIs in the treatment of depression 
 
101 
Thompson S. M. and Gahwiler B. H. (1992) Comparison of the actions of baclofen at pre- and 
postsynaptic receptors in the rat hippocampus in vitro. J Physiol 451, 329-345. 
Trillat A. C., Malagie I., Scearce K., Pons D., Anmella M. C., Jacquot C., Hen R. and Gardier A. 
M. (1997) Regulation of serotonin release in the frontal cortex and ventral hippocampus of 
homozygous mice lacking 5-HT1B receptors: in vivo microdialysis studies. J Neurochem 69, 
2019-2025. 
Urwyler S., Gjoni T., Koljatic J. and Dupuis D. S. (2005) Mechanisms of allosteric modulation at 
GABAB receptors by CGP7930 and GS39783: effects on affinities and efficacies of orthosteric 
ligands with distinct intrinsic properties. Neuropharmacology 48, 343-353. 
Varga V., Sik A., Freund T. F. and Kocsis B. (2002) GABA(B) receptors in the median raphe 
nucleus: distribution and role in the serotonergic control of hippocampal activity. Neuroscience 
109, 119-132. 
Vohora D. (2004) Histamine-selective H3 receptor ligands and cognitive functions: an overview. 
IDrugs 7, 667-673. 
Wade A., Crawford G. M., Angus M., Wilson R. and Hamilton L. (2003) A randomized, double-
blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in 
depressed patients in primary care. Int Clin Psychopharmacol 18, 133-141. 
Weikop P., Kehr J. and Scheel-Kruger J. (2004) The role of alpha1- and alpha2-adrenoreceptors 
on venlafaxine-induced elevation of extracellular serotonin, noradrenaline and dopamine levels in 
the rat prefrontal cortex and hippocampus. J Psychopharmacol 18, 395-403. 
Wilcox C. S., Ferguson J. M., Dale J. L. and Heiser J. F. (1996) A double-blind trial of low- and 
high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients. 
Psychopharmacol Bull 32, 335-342. 
Winter J. C. and Rabin R. A. (1993) Antagonism of the stimulus effects of yohimbine and 8-
hydroxydipropylaminotetralin. Pharmacol Biochem Behav 44, 851-855. 
Wirtshafter D. and Sheppard A. C. (2001) Localization of GABA(B) receptors in midbrain 
monoamine containing neurons in the rat. Brain Res Bull 56, 1-5. 
Zhang W., Perry K. W., Wong D. T., Potts B. D., Bao J., Tollefson G. D. and Bymaster F. P. 
(2000a) Synergistic effects of olanzapine and other antipsychotic agents in combination with 
fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. 
Neuropsychopharmacology 23, 250-262. 
Zhang Y., Raap D. K., Garcia F., Serres F., Ma Q., Battaglia G. and Van de Kar L. D. (2000b) 
Long-term fluoxetine produces behavioral anxiolytic effects without inhibiting neuroendocrine 
responses to conditioned stress in rats. Brain Res 855, 58-66. 
Chapter 3 
102 
   
